

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome

Authors

Ian M. Bouligny,¹ Guillermo Montalban-Bravo,¹ Koji Sasaki,¹ Naval Daver,¹ Elias Jabbour,¹ Yesid Alvarado,¹ Courtney D. DiNardo,¹ Farhad Ravandi,¹ Gautam Borthakur,¹ Prithviraj Bose,¹ Naveen Pemmaraju,¹ Steven Kornblau,¹ Tapan Kadia,¹ Lucia Masarova,¹ Koichi Takahashi,¹ Michael Andreeff,¹ Alexandre Bazinet,¹ Hui Yang,¹ Rashmi Kanagal-Shamanna,² Chitra Hosing,³ Sherry Pierce,¹ Meghan Meyer,¹ Xuelin Huang⁴ and Guillermo Garcia-Manero¹

¹Department of Leukemia; ²Department of Hematopathology;

³Department of Stem Cell Transplantation and Cellular Therapy and

⁴Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Correspondence:

G. GARCIA-MANERO - ggarciam@mdanderson.org

<https://doi.org/10.3324/haematol.2024.286559>

Received: August 30, 2024.

Accepted: February 13, 2025.


Early view: February 20, 2025.

©2025 Ferrata Storti Foundation

Published under a CC BY-NC license



Supplementary Appendix




Supplementary Figure 1. Forest plot of predictors of overall survival with stem cell transplant as a time-dependent covariate for patients treated with azacitidine-ipilimumab, azacitidine-nivolumab, and azacitidine-ipilimumab-nivolumab. Sixty-four of 66 patients had next-generation sequencing performed prior to treatment.

	Azacitidine-ipilimumab (N = 33)	Azacitidine-nivolumab (N = 20)	Azacitidine- ipilimumab-nivolumab (N = 13)
Hematologic toxicities, grade ≥ 3 (%)			
Leukopenia	19 (57.6)	15 (75.0)	13 (100.0)
Neutropenia	23 (69.7)	17 (85.0)	13 (100.0)
Lymphocytopenia	14 (42.2)	8 (40.0)	11 (84.6)
Anemia	21 (63.6)	11 (55.0)	9 (69.2)
Thrombocytopenia	25 (75.8)	17 (85.0)	13 (100.0)
Non-hematologic toxicities, grade ≥ 3 (%)			
Neutropenic fever	6 (18.2)	4 (20.0)	6 (46.2)
Infection	7 (21.2)	9 (45.0)	6 (46.2)
Fatigue	0	0	0
Pneumonia	5 (15.2)	7 (35.0)	2 (15.4)
Pneumonitis	2 (6.1)	0	2 (15.4)
Respiratory failure or hypoxia	4 (12.1)	0	0
Hemorrhage	0	2 (10.0)	1 (7.7)
Abdominal pain	0	0	0
Vomiting	0	0	0
Diarrhea	0	0	0
Colitis	1 (3.0)	1 (5.0)	0
AST elevation	1 (3.0)	3 (15.0)	1 (7.7)
ALT elevation	2 (6.1)	3 (15.0)	2 (15.4)
Bilirubin elevation	0	1 (5.0)	0
Rash	1 (3.0)	0	3 (23.1)
Hyperthyroidism	0	0	0
Hypothyroidism	0	0	0
Creatinine increased	2 (6.1)	0	1 (7.7)
Death during induction (%)			
Death within 30 days	1 (3.0)	0	0
Death between 31 – 60 days	1 (3.0)	0	0

Supplementary Table 1. Grade ≥ 3 toxicities in patients treated with azacitidine-ipilimumab, azacitidine-nivolumab, and azacitidine-ipilimumab-nivolumab.

Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase.



Supplementary Figure 2. Time-to-event analyses for patients treated with azacitidine-ipilimumab, azacitidine-nivolumab, and azacitidine-ipilimumab-nivolumab. **(A)** Duration of response among IWG 2023 responders for all three cohorts. **(B)** Probability of event-free survival in all three cohorts. **(C)** Overall survival stratified by IPSS-R intermediate-risk disease and high or very high-risk disease. All cohorts are pooled. **(D)** Overall survival stratified by IPSS-M moderate- or high-risk disease. All cohorts are pooled. **(E)** Median time to the next line of therapy for relapsed or refractory disease for all three cohorts. **(F)** Non-landmarked analysis of overall survival in patients that underwent SCT for all three cohorts.